Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThere is no single 'best' dose of Mounjaro for weight loss — the right dose is the highest one your body tolerates well, reached gradually through a structured titration schedule. Treatment starts at 2.5 mg and steps up every four weeks, guided by a prescriber who reviews your response at each stage. These are prescription-only medicines; a clinician decides what is appropriate for you specifically. For most adults in clinical trials, meaningful weight loss accumulated as doses increased toward the 10 mg, 12.5 mg and 15 mg range, with tirzepatide (Mounjaro) achieving average reductions of around 20–21% of body weight at the 15 mg maintenance dose in the SURMOUNT-1 trial, published in the New England Journal of Medicine.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A question our prescribers hear most weeks is some version of: 'I've been on 2.5 mg for a month and barely anything has changed, is it working?' The short answer is that it's doing exactly what it's supposed to. The first pen's job is to let your gut adapt to tirzepatide's dual GIP and GLP-1 receptor activity before you move to a dose that carries genuine therapeutic weight. Nausea and digestive discomfort are most common in the opening weeks, and starting low reduces how sharply they hit.
Four weeks in, your prescriber reviews your response. If you've tolerated the starting dose without significant problems, titration to 5 mg follows. The 5 mg pen is where most people first notice appetite beginning to shift. This is still the early part of the schedule, don't judge the treatment's potential here.
For context, the full Mounjaro dose structure for weight loss follows a standardised ladder: 2.5 mg, then 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, each typically held for around four weeks before a step up. That's a minimum of roughly six months to reach the highest licensed dose, assuming tolerability at each stage.
Clinical trial data from SURMOUNT-1 makes the dose-response relationship clear: weight loss was greater at each successively higher dose. Adults taking 10 mg lost more on average than those on 5 mg; 15 mg produced the strongest results of all. The 15 mg dose is the licensed maximum and the one associated with approximately 20–21% average body-weight reduction over 72 weeks. NICE's appraisal of tirzepatide references this evidence directly in its recommendation, available at NICE TA1026.
This doesn't mean 15 mg is guaranteed to be your dose. Some people lose substantial weight at 10 mg and tolerate it better than the step to 12.5 mg. A prescriber will weigh your weight trajectory, side-effect burden and overall health picture before recommending any increase. Pushing to the maximum dose is not always the right clinical call.
It's worth noting that cost changes with dose too. If you want to understand how pricing shifts as the schedule progresses, the Mounjaro cost guide covers what to expect at each stage from a private clinic.
Once you've reached a dose that's producing steady, tolerable progress, the clinical conversation shifts from 'should we go higher?' to 'is this the right place to stay?' Not everyone needs to reach 15 mg. NICE's guidance on tirzepatide suggests that if less than 5% weight loss has occurred after six months at the highest tolerated dose, continuing should be reviewed, a threshold that reflects the medicine's intended purpose alongside a reduced-calorie diet and increased physical activity.
If side effects become difficult at a given dose, a prescriber may recommend holding at the previous level rather than pushing through. This is a legitimate, common outcome. What counts as the best dose is ultimately individual: it's the dose at which your weight loss is clinically meaningful and your quality of life stays intact. The 15 mg ceiling is the maximum the MHRA licence permits, no prescriber should go beyond it.
The NHS tirzepatide medicines page provides patient-level information on how tirzepatide works and what to expect during treatment, including when to contact a clinician if side effects become a concern.
The dose schedule matters when you're picking a provider because not all services handle titration with the same rigour. A legitimate, clinician-led service reviews your case before each repeat, checks that a dose increase is clinically appropriate and considers your whole picture, not just your subscription status. That clinical re-review before every order is how the way nume is set up differs from services that treat repeat supply as automatic.
If you're already on Mounjaro elsewhere and want to transfer, a prescriber here will ask for evidence of your current dose and treatment history before continuing, that's standard safe practice, not an obstacle. Common questions about transferring are covered in our FAQ section. You can explore all weight-loss treatment options before deciding, or if you're ready to have your circumstances assessed, start with a free consultation with our prescribers.
Mounjaro is a prescription-only medicine. Suitability is assessed individually; the right dose for someone else isn't the guide for yours. Start your free consultation and a GPhC-registered Independent Prescriber will review your case the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.